Strong Buy Rating for Replimune Group Due to Promising RP1 + Opdivo Results and Favorable FDA Review
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Replimune Group (REPL – Research Report), with a price ...
Managed Healthcare Executive3h
BLA Accepted for Melanoma Combination Therapy, RP1 and Nivolumab
The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22 ...
Replimune price target raised to $27 from $18 at BMO Capital
BMO Capital analyst Evan Seigerman raised the firm’s price target on Replimune (REPL) to $27 from $18 and keeps an Outperform rating on the ...
Zacks.com on MSN7h
REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA
The FDA accepts and grants priority review to Replimune's BLA for RP1 in combination with Opdivo for advanced melanoma. A decision is due on Jul.
The Pharma Letter10h
FDA accepts Replimune’s melanoma candidate for priority review
The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RP1 (vusolimogene ...